Compared to controls, the immunomodulatory agent groups (OX40 agonist only, PD-1 inhibitor only and dual combination) significantly delay tumor growth (p < 0.0001), however no difference was observed between the different schemes (p = 0.59; Supplementary Figure S1). Here, TNFRSF4 is linked to neoplasm.